Comparative Preclinical Evaluation of the Safety, Antifungal Activity, and Pharmacokinetics of Sertaconazole Products for External Use

SCIENTIFIC RELEVANCE. The high prevalence of fungal skin infections motivates expanding the range of sertaconazole products for external use.

AIM. The study was a preclinical comparison of the safety, antifungal activity, and pharmacokinetics of Sertaverin® 2% medicated shampoo (VERTEX JSC, Russia) with those of Sertamicol® 2% solution for external use (Glenmark Pharmaceuticals Ltd, India) and Nizoral® 2% shampoo (Janssen Pharmaceuticals N.V., Belgium) approved in the Russian Federation.

MATERIALS AND METHODS. In the toxicity study, the medicinal products were applied to the skin of male and female outbred rats at doses of 0.5 or 1.5 mL/animal for 28 days. The authors evaluated the pharmacokinetics of two sertaconazole formulations (shampoo and solution) following a single administration to adult male rats at the same dose. Nizoral® was not used in the pharmacokinetics study because it contains a different active substance, ketoconazole. The minimum inhibitory concentration (MIC) was determined using the serial microdilution method in a wide range of concentrations.

RESULTS. The medicinal products did not exhibit any significant toxic effects in laboratory animals after 28 days of repeated dermal application. Plasma sertaconazole concentrations were negligible. Sertaconazole was intensively distributed in the liver, which is a highly vascularised organ, and in the target organ (skin at the site of application). The relative bioavailability of sertaconazole from the shampoo relative to that from the solution for external use was approximately 30% in liver tissues and approximately 363% in skin tissues at the application site. Sertaverin® was comparable to sertaconazole in the active substance form in terms of inhibiting the growth of Malassezia furfur strains. The MICs calculated on the active substance basis were ≤16–64 μg/mL.

CONCLUSIONS. With its synergistic dual mechanism of action, broad-spectrum antifungal activity, lipophilic properties, and low systemic absorption, Sertaverin® may provide a more effective and safe alternative to marketed medicinal products for scalp diseases.

1. Peyrí J, Lleonart M, the Spanish Group of the SEBDERM Study. Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis. Actas Dermosifiliogr. 2007;98(7):476–82 (In Spanish). https://doi.org/10.1016/s1578-2190(07)70491-2

2. Kim GK. Seborrheic dermatitis and malassezia species: How are they related? J Clin Aesthet Dermatol. 2009;2(11):14–7. PMID: 20725575

3. Agut J, Palacín C, Salgado J, Casas E, Sacristán A, Ortiz JA. Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung. 1992;42(5A):721–4. PMID: 1627191

4. Farré M, Ugena B, Badenas JM, Márquez M, Roset P, Ortiz JA. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittelforschung. 1992;42(5A):752–4. PMID: 1627199

5. Matushevskaya EV, Svyrzhevskaya EV. Topical forms of sertaconazole in the treatment of fungal infections of the skin. Vestnik Dermatologii i Venerologii. 2014;(5):106–11 (In Russ.). https://doi.org/10.25208/0042-4609-2014-90-5-106-111

6. Pedragosa R, González B, Martín M, Herrero E, Roset P, Márquez M, et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of cutaneous dermatophytosis. Arzneimittelforschung. 1992;42(5A):760–3. PMID: 1627202

7. Carrillo-Muñoz AJ, Tur-Tur C, Giusiano G, Marcos-Arias C, Eraso E, Jauregizar N, Quindós G. Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. Expert Rev Anti Infect Ther. 2013;11(4):347–58. https://doi.org/10.1055/s-0031-1296869

8. Alomar C, Bassas S, Casas M, Crespo V, Ferrándiz C, Fonseca E, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung. 1992;42(5A):767–73. https://doi.org/10.1016/j.diagmicrobio.2006.04.006

9. Pfaller MA, Sutton DA. Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. Diagn Microbiol Infect Dis. 2006;56(2):147–52. https://doi.org/10.1016/j.diagmicrobio.2006.04.006

10. Manian M, Madrasi K, Chaturvedula A, Banga AK. Investigation of the dermal absorption and irritation potential of sertaconazole nitrate anhydrous gel. Pharmaceutics. 2016;8(3):21. https://doi.org/10.3390/pharmaceutics8030021

11. Susilo R, Korting HC, Strauss UP, Menke G, Schuster O, Menke A. Rate and extent of percutaneous absorption of sertaconazole nitrate after topical administration. Arzneimittelforschung. 2005;55(6):338–42. https://doi.org/10.1055/s-0031-1296869

12. Tavakoli N, Taymouri S, Saeidi A, Akbari V. Thermosensitive hydrogel containing sertaconazole loaded nanostructured lipid carriers for potential treatment of fungal keratitis. Pharm Dev Technol. 2019;24(7):891–901. https://doi.org/10.1080/10837450.2019.1616755

13. Russell WMS, Burch RL. The principles of humane experimental technique. London: Methuen and Co; 1959.

14. Bland JM. An introduction to medical statistics. New York: Oxford University Press; 2000.

15. Altman DG, Bland JM. How to randomise. BMJ. 1999;319(7211):703–4. https://doi.org/10.1136/bmj.319.7211.703

16. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306–14. https://doi.org/10.1016/j.cmpb.2010.01.007

17. Mandlik SK, Siras SS. RP-HPLC method development and validation for the estimation of sertaconazole nitrate in bulk and tablet dosage form. Int J Chemtech Res. 2017;10(1):573–80.

18. Rizk M, Toubar SS, El-Alamin MMA, Azab MMM. Micellar liquid chromatographic determination of sertaconazole and terconazole in bulk, pharmaceutical dosage forms and spiked human plasma. Bul Fac Pharm Cairo Univ. 2014;52(1):155–64. https://doi.org/10.1016/j.bfopcu.2014.03.002

19. Wang Y, Pang L, Wu M, Ou N. A validated LC-MS/ MS method for determination of sertaconazole nitrate in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(31):4047–50. https://doi.org/10.1016/j.jchromb.2009.09.032

20. Van Gerven F, Odds F.C. The anti-Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Mycoses. 1995;38(9–10):389–93. https://doi.org/10.1111/j.1439-0507.1995.tb00070.x